Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Journal of Infectious Diseases

Topics

Medicine

Internal Medicine

Infectious Diseases

Virology

Pharmacology

Show all topics

DOI

10.1093/infdis/jiu051

License

CC-BY-NC-ND

Other Formats

PDF